L. johnsonii

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the provided abstracts, Lactobacillus johnsonii has been most studied in the context of gut-mediated inflammation and barrier function, particularly in experimental colitis models and diet–microbiome interactions (e.g., β-glucan and galactooligosaccharides). A recurring theme is that L. johnsonii abundance decreases in disease or injury states (e.g., colitis, high-copper–induced intestinal damage, progressive CKD-associated dysbiosis) and that restoring it via supplementation or diet-associated enrichment can improve host phenotypes. Mechanistic work has focused on microbial metabolites and host signaling pathways, especially tryptophan-derived indoles (e.g., indole-3-lactic acid, indole-3-aldehyde) and downstream aryl hydrocarbon receptor (AhR/AHR) signaling, as well as short-chain fatty acid (SCFA) ecology (notably butyrate) and competitive exclusion of enteric pathogens (e.g., reduced Salmonella adhesion/invasion in epithelial models).

The strongest evidence in these abstracts supports a causal, protective role for L. johnsonii in multiple animal models when directly supplemented or when its abundance is increased by dietary interventions, with measurable improvements in tissue pathology and barrier markers. In colitis, multi-omics and loss-of-function approaches link β-glucan–driven enrichment of L. johnsonii to increased indole-3-lactic acid and AhR activation, with an additional, well-defined cross-feeding interaction in which Bacteroides uniformis degrades β-glucan and produces nicotinamide that promotes L. johnsonii growth; a small proof-of-concept human study supports increases in L. johnsonii/B. uniformis and indole metabolites after β-glucan. In CKD models, L. johnsonii supplementation is associated with higher serum indole-3-aldehyde and reduced renal injury, with partial dependence on AHR signaling demonstrated using AHR-deficient systems. In high-copper diet–associated colonic injury, extinction of L. johnsonii is linked to reduced SCFAs and barrier damage, and rescue experiments suggest benefits are mediated in part by restoration of butyrate-producing community members and barrier integrity (with butyrate, but not acetate, phenocopying key effects).

Key gaps include limited direct clinical evidence for therapeutic efficacy: most causal data are from rodents, piglets, and in vitro systems, while human data are largely associative or short-term dietary proof-of-concept rather than randomized controlled trials of defined L. johnsonii strains. Additional research is needed to resolve strain-specificity and context-dependence (e.g., differential effects among Lactobacillus species under GOS; potential divergence in AhR/AHR modulation across disease settings), to standardize dosing and colonization dynamics, and to clarify whether benefits arise from L. johnsonii itself versus community-level restructuring (e.g., enrichment of butyrate producers). Finally, mechanistic uncertainties remain around metabolite causality and host targets (e.g., when AhR activation vs suppression is beneficial, and how indole and SCFA pathways interact), and safety/efficacy should be evaluated in well-powered, placebo-controlled trials in CKD, inflammatory bowel disease, and infection-related barrier dysfunction.

1. What conditions has L. johnsonii been studied for?

  • Chronic kidney disease (CKD) progression and renal injury (human observational microbiome data plus multiple rat/mouse CKD models; mechanistic cell work).

  • Inflammatory bowel disease models / colitis (DSS-induced colitis; β-glucan intervention studies implicating L. johnsonii; additional mouse work with co-administration alongside Bacteroides thetaiotaomicron).

  • Enteric infection and intestinal barrier dysfunction

    • Salmonella infection (mouse model with GOS-enriched lactobacilli; piglet model with Salmonella Infantis).

    • High-copper diet–induced colonic barrier damage (pig model and fecal microbiota transplantation into antibiotic-treated mice; rescue with L. johnsonii).

  • Fungal overgrowth and Candida-associated dysbiosis in colitis (mouse DSS colitis model; interactions with Candida spp.).

  • Type 1 diabetes mellitus (T1DM)

    • Clinical trial context: a randomized, double-blind, placebo-controlled trial of “probiotic strains” in children/adolescents with T1DM (abstract does not clearly specify L. johnsonii as a component).

    • Preclinical: BioBreeding diabetes-prone rats fed L. johnsonii showed reduced diabetes incidence (mechanistic follow-up mentioned).

  • General antimicrobial/anti-infectious probiotic activity (review notes L. johnsonii NCC 533 as one of a small set of well-characterized probiotic Lactobacillus strains with antimicrobial effects evaluated in clinical trials for GI pathogens/rotavirus, though specific trial outcomes are not detailed in the provided excerpt).

2. Does it work in treating those conditions? Summarize the evidence.

  • CKD / renal injury: promising preclinical evidence; human data are correlational.

    • In a 480-participant microbiomics study (healthy controls + stage 1–5 CKD), a taxonomic chain including Lactobacillus johnsonii correlated with CKD progression and kidney clinical markers; abundance was reduced with progressive CKD in adenine-induced CKD rats.

    • Supplementation with L. johnsonii ameliorated kidney lesions in CKD rats.

    • Mechanism proposed: L. johnsonii increased serum indole-3-aldehyde (IAld), which was negatively correlated with creatinine in CKD rats and decreased in late CKD patients; IAld treatment reduced kidney lesions and suppressed AHR signaling. The IAld benefit was partially diminished in AHR-deficient mice/cells, supporting (but not proving) causality through AHR.

    • Limitation: no human supplementation trial is described; the human component is association, not proof of clinical efficacy.

  • Colitis: multiple mouse studies suggest benefit, with mechanistic pathways identified.

    • β-glucan intervention in colitic mice ameliorated colitis and reversed Lactobacillus reduction; L. johnsonii was the most significantly enriched Lactobacillus species and its abundance was negatively correlated with colitis severity.

    • Multi-omics suggested L. johnsonii produced indole-3-lactic acid (ILA) that activates AhR, linked to mitigation of colitis. (Note: this contrasts with the CKD abstract where suppressing AHR signaling was protective; these abstracts imply context-dependent AhR biology.)

    • In DSS colitis, oral L. johnsonii (with B. thetaiotaomicron) reduced overgrowth of pathobionts (e.g., E. coli, E. faecalis, Candida glabrata) and reduced inflammatory parameters; effects were associated with increased TLR9 expression and chitinase-like protein-1 activation.

    • Human evidence in the provided text: a proof-of-concept study in healthy individuals showed β-glucan increased L. johnsonii and B. uniformis abundance and increased ILA levels, but this is not a colitis treatment trial.

  • Salmonella infection / barrier dysfunction: mixed and strain-/context-dependent.

    • In Salmonella-infected mice after GOS enrichment, L. delbrueckii (not L. johnsonii) reduced inflammation via propionate/JAK2-STAT3/M1 macrophage pathways; L. johnsonii did not show the same anti-inflammatory protection in that model but did inhibit Salmonella adhesion and invasion in epithelial cells via competitive exclusion.

    • In weaned piglets, oral L. johnsonii L531 decreased Salmonella Infantis colonization, accelerated fecal clearance, reduced translocation to spleen, mitigated SCFA depletion, and improved growth/feed conversion versus infected controls.

    • Takeaway: efficacy appears to depend on strain, host, and outcome measured (anti-adhesion vs systemic inflammation).

  • High-copper diet–induced colonic damage: supportive preclinical evidence.

    • High copper caused colonic damage, Lactobacillus extinction (including confirmed extinction of L. johnsonii), and reduced acetate/butyrate in pigs; transplanting copper-rich microbiota reproduced features in antibiotic-treated mice.

    • L. johnsonii “rescue” restored SCFAs and improved barrier outcomes (mucus thickness, colon length, tight junction proteins).

    • Mechanistic finding: protection required restoration of butyrate production; butyrate (not acetate) corrected barrier damage, and L. johnsonii rescue enriched butyrate-producing taxa (notably Lachnospiraceae NK4A136 group) enabling acetate-to-butyrate conversion.

  • T1DM: suggestive but incomplete evidence in the provided abstracts.

    • BioBreeding diabetes-prone rats fed L. johnsonii had decreased diabetes incidence (preclinical).

    • A pediatric T1DM randomized controlled trial reported improved glycemic outcomes (HbA1c) and immune cytokines with “probiotics + insulin” vs insulin alone, but the abstract excerpt does not specify whether L. johnsonii was included, so it cannot be attributed to L. johnsonii from the provided text.

3. What health benefits does it have?

  • Renal protective effects (preclinical): L. johnsonii supplementation reduced kidney lesions in CKD rat models, plausibly via increasing IAld and modulating AHR signaling.

  • Anti-inflammatory and microbiome-modulating effects in colitis models:

    • Associated with reduced colitis severity and restoration of Lactobacillus levels in mice given β-glucan.

    • Production of tryptophan-derived indoles (e.g., ILA) linked to AhR-related immune modulation in colitis models.

  • Barrier support and SCFA-related benefits (preclinical): in high-copper diet models, restoring L. johnsonii helped normalize SCFA pathways and improved mucus/tight junction integrity; in piglets L. johnsonii L531 produced/maintained SCFAs and supported growth performance during infection stress.

  • Anti-pathogen effects:

    • Competitive exclusion against Salmonella adhesion/invasion in epithelial cells (strain BNCC 186110 in the GOS study).

    • Reduced Salmonella colonization and translocation in piglets (strain L531).

    • Anti-Candida activity (with B. thetaiotaomicron) via chitinase-/mannosidase-like activities and associated reduction in inflammatory parameters in DSS colitis.

  • Potential to be leveraged via prebiotics and cross-feeding: β-glucan increased L. johnsonii in mice and in a proof-of-concept human study, apparently via cross-feeding where B. uniformis degrades β-glucan and produces nicotinamide that promotes L. johnsonii growth.

4. Does it have any downsides or side effects?

  • Direct adverse effects are not reported in the provided abstracts. The animal supplementation studies described (CKD, colitis, piglet infection, high-copper rescue) do not mention safety signals in the excerpts provided.

  • Mechanistic caution: context-dependent AhR effects. One abstract links benefit in colitis to activation of AhR by an L. johnsonii metabolite (ILA), while the CKD abstract links benefit to suppression of AHR signaling via IAld. This suggests that immune/metabolic effects could be tissue- and disease-context specific, and it is not yet clear what the net effect would be in humans with comorbidities.

  • Strain- and indication-specific efficacy (and therefore risk of “non-benefit”). In the GOS/Salmonella mouse work, L. johnsonii did not replicate the anti-inflammatory protection seen with L. delbrueckii, even though it reduced Salmonella adhesion/invasion in vitro. This implies that choosing the wrong strain/outcome could lead to limited clinical benefit.

  • General probiotic caveat (not evidenced in these abstracts): In broader clinical practice, probiotics can rarely cause infections in severely immunocompromised or critically ill patients; however, this risk is not discussed or demonstrated in the provided abstracts.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • AHR pathway genetics are directly implicated in preclinical CKD benefit. The CKD abstract reports that IAld’s renoprotective effect was partially diminished in AHR-deficient mice and cells, and L. johnsonii’s effect was linked to IAld and AHR signaling. This implies that host variation that reduces AHR function (or downstream signaling) could reduce benefit from an IAld/L. johnsonii mechanism in CKD-like contexts.

  • TLR9-related signaling is implicated in colitis protection (mouse data). In DSS colitis, L. johnsonii (with B. thetaiotaomicron) was associated with “high TLR9 expression” and reduced inflammatory mediators. While not a genetic study, it suggests that host genetic variants affecting TLR9 signaling could plausibly modify response; this is not directly tested in the provided abstracts.

  • No human pharmacogenomic findings are provided. None of the excerpts report genotype-stratified outcomes in humans (e.g., AHR polymorphisms, immune receptor variants), so any pharmacogenomic conclusions beyond the AHR-deficiency animal model are speculative.

References

  1. Targeting Lactobacillus johnsonii to reverse chronic kidney disease.
    Hua Miao, Fei Liu, Yan-Ni Wang, Xiao-Yong Yu, Shougang Zhuang, Yan Guo, Nosratola D Vaziri, Shi-Xing Ma, Wei Su, You-Quan Shang, Ming Gao, Jin-Hua Zhang, Li Zhang, Ying-Yong Zhao, Gang Cao (2024) - Signal transduction and targeted therapy
  2. Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis.
    Shanshan Zhang, Qixing Nie, Yonggan Sun, Sheng Zuo, Chunhua Chen, Song Li, Jingrui Yang, Jielun Hu, Xingtao Zhou, Yongkang Yu, Ping Huang, Lu Lian, Mingyong Xie, Shaoping Nie (2024) - Microbiome
  3. Lactobacillus johnsonii alleviates colitis by TLR1/2-STAT3 mediated CD206+ macrophagesIL-10 activation.
    Ding-Jia-Cheng Jia, Qi-Wen Wang, Ying-Ying Hu, Jia-Min He, Qi-Wei Ge, Ya-Dong Qi, Lu-Yi Chen, Ying Zhang, Li-Na Fan, Yi-Feng Lin, Yong Sun, Yao Jiang, Lan Wang, Yan-Fei Fang, Hui-Qin He, Xiong-E Pi, Wei Liu, Shu-Jie Chen, Liang-Jing Wang (2022) - Gut microbes
  4. Strain specificity of lactobacilli with promoted colonization by galactooligosaccharides administration in protecting intestinal barriers during Salmonella infection.
    Yujun Wu, Xiangyu Zhang, Xiaoyi Liu, Yi Li, Dandan Han, Yu Pi, Melanie A Whitmore, Xingmiao Lu, Guolong Zhang, Jinkai Zheng, Junjun Wang (2024) - Journal of advanced research
  5. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents.
    Vanessa Liévin-Le Moal, Alain L Servin (2014) - Clinical microbiology reviews
  6. Sishen Pill inhibits intestinal inflammation in diarrhea mice via regulating kidney-intestinal bacteria-metabolic pathway.
    Xiaoya Li, Bo Qiao, Yueying Wu, Na Deng, Jiali Yuan, Zhoujin Tan (2024) - Frontiers in pharmacology
  7. Blocked conversion of Lactobacillus johnsonii derived acetate to butyrate mediates copper-induced epithelial barrier damage in a pig model.
    Yang Wen, Luqing Yang, Zhenyu Wang, Xiaoyi Liu, Meng Gao, Yunhui Zhang, Junjun Wang, Pingli He (2023) - Microbiome
  8. Adjuvant Probiotics of
    Chung-Hsing Wang, Hung-Rong Yen, Wen-Li Lu, Hsieh-Hsun Ho, Wen-Yang Lin, Yi-Wei Kuo, Yen-Yu Huang, Shin-Yu Tsai, Hung-Chih Lin (2022) - Frontiers in endocrinology
  9. Oleic Acid and Palmitic Acid from
    Rogatien Charlet, Chrystelle Le Danvic, Boualem Sendid, Patricia Nagnan-Le Meillour, Samir Jawhara (2022) - Microorganisms
  10. Lactobacillus johnsonii L531 reduces pathogen load and helps maintain short-chain fatty acid levels in the intestines of pigs challenged with Salmonella enterica Infantis.
    Ting He, Yao-Hong Zhu, Jiao Yu, Bing Xia, Xiao Liu, Gui-Yan Yang, Jin-Hui Su, Liang Guo, Meng-Ling Wang, Jiu-Feng Wang (2019) - Veterinary microbiology
  11. Bacteroides thetaiotaomicron and Lactobacillus johnsonii modulate intestinal inflammation and eliminate fungi via enzymatic hydrolysis of the fungal cell wall.
    Rogatien Charlet, Clovis Bortolus, Boualem Sendid, Samir Jawhara (2020) - Scientific reports
  12. Lactobacillus johnsonii inhibits indoleamine 2,3-dioxygenase and alters tryptophan metabolite levels in BioBreeding rats.
    Ricardo Valladares, Lora Bojilova, Anastasia H Potts, Evan Cameron, Christopher Gardner, Graciela Lorca, Claudio F Gonzalez (2013) - FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  13. The Effects ofLactobacillus johnsoniion Diseases and Its Potential Applications
    Ziyi Zhang, Lanlan Zhao, Jiacheng Wu, Yingmiao Pan, Guoping Zhao (2023)
  14. Microbiota-Derived Inosine Suppresses Systemic Autoimmunity via Restriction of B Cell Differentiation and Migration.
    Lingyu Gao, Yuhan Zhang, Zhi Hu, Shengwen Chen, Qiaolin Wang, Yong Zeng, Huiqi Yin, Junpeng Zhao, Yijing Zhan, Changxing Gao, Yue Xin, Bing Chen, Stijn van der Veen, Ming Zhao, Deyu Fang, Qianjin Lu (2025) - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  15. Dietary
    Zhiguo Li, Mengyu Li, Xuexun Fang, Dahai Yu, Xin Hu (2024) - Food & function
  16. Chronic Stress Dampens Lactobacillus Johnsonii-Mediated Tumor Suppression to Enhance Colorectal Cancer Progression.
    Qiuhua Cao, Mingrui Zhao, Yali Su, Siliang Liu, Yanting Lin, Huijuan Da, Chongxiu Yue, Yiming Liu, Dongquan Jing, Qixiang Zhao, Ning Liu, Juan Du, Zhanjie Zuo, Yao Fu, Anqi Chen, Lutz Birnbaumer, Yong Yang, Beiying Dai, Xinghua Gao (2024) - Cancer research
  17. Lactobacillus johnsonii BFE6154 Ameliorates Diet-Induced Hypercholesterolemia.
    Hongsup Yoon, Yuri Lee, Haryung Park, Hye-Ji Kang, Yosep Ji, Wilhelm H Holzapfel (2023) - Probiotics and antimicrobial proteins
  18. Insights From theLactobacillus johnsoniiGenome Suggest the Production of Metabolites With Antibiofilm Activity Against the PathobiontCandida albicans
    Roberto Vazquez-Munoz, Angela Thompson, Jordan T Russell, Takanori Sobue, Yanjiao Zhou (2022)
  19. Genomic analysis and functional properties of
    Mengdi Zhao, Yueyao Li, Yuanyuan Zhang, Guangyu Li (2024) - Frontiers in microbiology
  20. Sheep-Derived
    Zhuo Wang, Yuwei Zhao, Dingkun Fan, Jixian Zhang, Qiyu Diao, Kai Cui (2025) - Microorganisms


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!